Insider Trading Alert - REGN, FB And GNTX Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 12, 2014, 128 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $79.73 to $121,490,730.00.

Highlighted Stocks Traded by Insiders:

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Vagelos P Roy who is Chairman of the Board at Regeneron Pharmaceuticals sold 11,475 shares at $325.10 on Feb. 12, 2014. Following this transaction, the Chairman of the Board owned 103,275 shares meaning that the stake was reduced by 10% with the 11,475-share transaction.

The shares most recently traded at $317.90, down $7.20, or 2.26% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares sold: 4,000
  • 12-Week # shares sold: 13,000
  • 24-Week # shares sold: 18,000

The average volume for Regeneron Pharmaceuticals has been 842,900 shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $31.8 billion and is part of the health care sector and drugs industry. Shares are up 16.4% year-to-date as of the close of trading on Wednesday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 40.0. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Facebook (FB) - FREE Research Report

Sandberg Sheryl who is Chief Operating Officer at Facebook sold 283,334 shares at $64.61 on Feb. 12, 2014. Following this transaction, the Chief Operating Officer owned 10.1 million shares meaning that the stake was reduced by 2.74% with the 283,334-share transaction.

Schroepfer Michael Todd who is Chief Technology Officer at Facebook sold 25,000 shares at $64.28 on Feb. 12, 2014. Following this transaction, the Chief Technology Officer owned 332,966 shares meaning that the stake was reduced by 6.98% with the 25,000-share transaction.

Athwal Jas who is Chief Accounting Officer at Facebook sold 28,000 shares at $63.76 on Feb. 12, 2014. Following this transaction, the Chief Accounting Officer owned 122,807 shares meaning that the stake was reduced by 18.57% with the 28,000-share transaction.

The shares most recently traded at $65.26, up $1.50, or 2.3% since the insider transaction. Historical insider transactions for Facebook go as follows:

  • 4-Week # shares sold: 355,634
  • 12-Week # shares sold: 2.0 million
  • 24-Week # shares sold: 3.7 million

The average volume for Facebook has been 64.0 million shares per day over the past 30 days. Facebook has a market cap of $128.1 billion and is part of the technology sector and internet industry. Shares are up 17.93% year-to-date as of the close of trading on Wednesday.

Facebook, Inc. operates as a social networking company worldwide. It provides a set of development tools and application programming interfaces that enable developers to integrate with Facebook to create mobile and Web applications. The company has a P/E ratio of 108.1. Currently there are 32 analysts that rate Facebook a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FB - FREE

TheStreet Quant Ratings rates Facebook as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full Facebook Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Gentex Corporation (GNTX) - FREE Research Report

Mulder John A who is Director at Gentex Corporation sold 12,000 shares at $31.43 on Feb. 12, 2014. Following this transaction, the Director owned 74,308 shares meaning that the stake was reduced by 13.9% with the 12,000-share transaction.

The shares most recently traded at $31.57, up $0.14, or 0.43% since the insider transaction. Historical insider transactions for Gentex Corporation go as follows:

  • 24-Week # shares sold: 10,986

The average volume for Gentex Corporation has been 1.0 million shares per day over the past 30 days. Gentex Corporation has a market cap of $4.6 billion and is part of the consumer goods sector and automotive industry. Shares are down 3.91% year-to-date as of the close of trading on Wednesday.

Gentex Corporation designs, develops, manufactures, and markets electro-optical products for the automotive, commercial building, and aircraft industries primarily in the United States, Germany, and Japan. The stock currently has a dividend yield of 1.78%. The company has a P/E ratio of 20.3. Currently there are 2 analysts that rate Gentex Corporation a buy, 2 analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNTX - FREE

TheStreet Quant Ratings rates Gentex Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Gentex Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

REPLAY: Jim Cramer on How to Navigate the Stock Market Amid Tariff Worries

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

Global Markets Hit Hard; AMC Entertainment Sells Stake in Ad Unit -- ICYMI

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

CVS, Walgreens and Citigroup: Cramer's 'Off the Charts'

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

Jim Cramer: 4 Stocks Could Get Throttled By a 'Knock Down Drag Out' With China

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens